• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于说明非结核分枝杆菌肺病管理良好实践的案例研究。

Case studies to illustrate good practice in the management of non-tuberculous mycobacterial pulmonary disease.

作者信息

Tiberi Simon, Lipman Marc C, Floto Andres

机构信息

Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.

Blizard Institute, Queen Mary University of London, London, UK.

出版信息

Respir Med Case Rep. 2022 May 23;38:101668. doi: 10.1016/j.rmcr.2022.101668. eCollection 2022.

DOI:10.1016/j.rmcr.2022.101668
PMID:35651519
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9149196/
Abstract

Pulmonary disease caused by non-tuberculous mycobacteria (NTM-PD) can be a complex condition for health care providers to manage, and delayed diagnosis and treatment failure are common. Here we present three case studies that illustrate key challenges in the diagnosis and treatment of NTM-PD, and provide guidance on these issues. In addition, we make recommendations on how the overall management of NTM-PD may be improved, through strategies such as physician education to recognise NTM-PD, and the development of multidisciplinary teams and patient-support groups.

摘要

非结核分枝杆菌引起的肺部疾病(NTM-PD)对于医护人员来说可能是一种复杂的病症,延迟诊断和治疗失败很常见。在此,我们展示三个案例研究,以说明NTM-PD诊断和治疗中的关键挑战,并就这些问题提供指导。此外,我们还就如何通过诸如提高医生对NTM-PD的识别能力的教育、发展多学科团队和患者支持小组等策略来改善NTM-PD的整体管理提出建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec3d/9149196/b9021ed9d95b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec3d/9149196/c1ac1fd643a4/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec3d/9149196/9cf4d05668f1/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec3d/9149196/b9021ed9d95b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec3d/9149196/c1ac1fd643a4/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec3d/9149196/9cf4d05668f1/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec3d/9149196/b9021ed9d95b/gr3.jpg

相似文献

1
Case studies to illustrate good practice in the management of non-tuberculous mycobacterial pulmonary disease.用于说明非结核分枝杆菌肺病管理良好实践的案例研究。
Respir Med Case Rep. 2022 May 23;38:101668. doi: 10.1016/j.rmcr.2022.101668. eCollection 2022.
2
Current and future management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) in the UK.英国非结核分枝杆菌肺病(NTM-PD)的当前和未来管理。
BMJ Open Respir Res. 2020 Jun;7(1). doi: 10.1136/bmjresp-2020-000591.
3
Non-tuberculous mycobacterial pulmonary disease (NTM-PD): Epidemiology, diagnosis and multidisciplinary management.非结核分枝杆菌肺病(NTM-PD):流行病学、诊断和多学科管理。
Clin Med (Lond). 2024 Jan;24(1):100017. doi: 10.1016/j.clinme.2024.100017. Epub 2024 Jan 17.
4
Best Practices for the Management of Patients with Non-Tuberculous Mycobacterial Pulmonary Disease According to a German Nationwide Analysis of Expert Centers.根据德国全国专家中心分析得出的非结核分枝杆菌肺病患者管理最佳实践
Healthcare (Basel). 2023 Sep 22;11(19):2610. doi: 10.3390/healthcare11192610.
5
Challenges of diagnosing and treating non-tuberculous mycobacterial pulmonary disease [NTM-PD]: A case series.非结核分枝杆菌肺病[NTM-PD]的诊断与治疗挑战:病例系列
J Clin Tuberc Other Mycobact Dis. 2021 Aug 30;25:100271. doi: 10.1016/j.jctube.2021.100271. eCollection 2021 Dec.
6
Non-tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide study.法国的非结核分枝杆菌肺部疾病:一项为期 8 年的全国性研究。
BMC Infect Dis. 2021 Nov 17;21(1):1165. doi: 10.1186/s12879-021-06825-x.
7
Microscopic polyangiitis secondary to Mycobacterium abscessus in a patient with bronchiectasis: a case report.分枝杆菌脓肿分枝杆菌继发显微镜下多血管炎支气管扩张症 1 例报告
BMC Pulm Med. 2018 Nov 19;18(1):170. doi: 10.1186/s12890-018-0732-3.
8
[Evaluation of the distribution of non-tuberculous mycobacteria strains isolated in National Tuberculosis Reference Laboratory in 2009-2010, Turkey].[2009 - 2010年土耳其国家结核病参考实验室分离的非结核分枝杆菌菌株分布评估]
Mikrobiyol Bul. 2012 Oct;46(4):560-7.
9
Diagnosis of non-tuberculous mycobacterial pulmonary disease (NTM-PD): modern challenges.非结核分枝杆菌肺部疾病(NTM-PD)的诊断:现代挑战。
Br J Radiol. 2020 Feb 1;93(1106):20190768. doi: 10.1259/bjr.20190768. Epub 2019 Dec 11.
10
Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases.非结核分枝杆菌肺病的共识管理推荐意见。
Lancet Infect Dis. 2022 Jul;22(7):e178-e190. doi: 10.1016/S1473-3099(21)00586-7. Epub 2022 Jan 25.

引用本文的文献

1
Supporting Patients with Nontuberculous Mycobacterial Pulmonary Disease: Ensuring Best Practice in UK Healthcare Settings.支持非结核分枝杆菌肺病患者:确保英国医疗环境中的最佳实践。
Pharmacy (Basel). 2024 Aug 21;12(4):126. doi: 10.3390/pharmacy12040126.

本文引用的文献

1
The Diagnosis of Nontuberculous Mycobacterial Pulmonary Disease by Single Bacterial Isolation Plus Anti-GPL-Core IgA Antibody.单一细菌分离加抗 GPL-Core IgA 抗体诊断非结核分枝杆菌肺病。
Microbiol Spectr. 2022 Feb 23;10(1):e0140621. doi: 10.1128/spectrum.01406-21. Epub 2022 Jan 5.
2
Non tuberculous mycobacteria pulmonary disease: patients and clinicians working together to improve the evidence base for care.非结核分枝杆菌肺病:患者与临床医生共同努力,改善护理的证据基础。
Int J Infect Dis. 2021 Dec;113 Suppl 1:S73-S77. doi: 10.1016/j.ijid.2021.03.064. Epub 2021 Mar 26.
3
What is important for people with nontuberculous mycobacterial disease? An EMBARC-ELF patient survey.
对于非结核分枝杆菌病患者来说什么是重要的?一项EMBARC-ELF患者调查。
ERJ Open Res. 2021 Feb 15;7(1). doi: 10.1183/23120541.00807-2020. eCollection 2021 Jan.
4
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.非结核分枝杆菌肺病治疗:美国胸科学会/欧洲呼吸学会/欧洲临床微生物学和传染病学会/美国感染病学会临床实践指南
Clin Infect Dis. 2020 Aug 14;71(4):e1-e36. doi: 10.1093/cid/ciaa241.
5
Current and future management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) in the UK.英国非结核分枝杆菌肺病(NTM-PD)的当前和未来管理。
BMJ Open Respir Res. 2020 Jun;7(1). doi: 10.1136/bmjresp-2020-000591.
6
Non-tuberculous mycobacterial lung disease in patients with bronchiectasis: perceived risk, severity and guideline adherence in a European physician survey.支气管扩张症患者的非结核分枝杆菌肺病:欧洲医师调查中的感知风险、严重程度和指南遵循情况。
BMJ Open Respir Res. 2020 Apr;7(1). doi: 10.1136/bmjresp-2019-000498.
7
British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease.英国胸科学会关于成人呼吸系统疾病患者使用长期大环内酯类药物的指南。
Thorax. 2020 May;75(5):370-404. doi: 10.1136/thoraxjnl-2019-213929. Epub 2020 Apr 17.
8
Non-tuberculous mycobacterial infections-A neglected and emerging problem.非结核分枝杆菌感染——一个被忽视和新兴的问题。
Int J Infect Dis. 2020 Mar;92S:S46-S50. doi: 10.1016/j.ijid.2020.02.022. Epub 2020 Feb 27.
9
Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis.大环内酯类耐药鸟分枝杆菌复合体肺病患者的临床特征和治疗结局:系统评价和荟萃分析。
Respir Res. 2019 Dec 18;20(1):286. doi: 10.1186/s12931-019-1258-9.
10
Diagnosis of non-tuberculous mycobacterial pulmonary disease (NTM-PD): modern challenges.非结核分枝杆菌肺部疾病(NTM-PD)的诊断:现代挑战。
Br J Radiol. 2020 Feb 1;93(1106):20190768. doi: 10.1259/bjr.20190768. Epub 2019 Dec 11.